
Verastem (NASDAQ:VSTM) is preparing a broad development program for its experimental cancer drug VS-7375, with incoming CEO Michael Bailey saying the company is considering both partnerships and a potential independent launch as it awaits midstage trial results.
At an investor discussion hosted by Jefferies, Bailey said data presented on Oct. 14, a $250 million financing and his appointment as incoming CEO changed the company’s outlook. He pointed to complete responses seen with VS-7375 as a single agent in previously treated patients, while emphasizing that future decisions will depend on the strength of additional data.
“We need to think about it as what we are really doing here. We would be potentially launching as the first G12D in pancreatic,” Bailey said, adding that the company would approach the larger opportunity step by step. He said there was interest from both investors and potential partners but that Verastem would consider all options for maximizing shareholder value.
Trial plans and potential approval paths
Verastem has started three phase 2 trials of VS-7375 in pancreatic, colorectal and lung cancer patients who have received at least one prior treatment, according to a speaker identified as “Operator” in the transcript. The company hopes each study could support an accelerated approval, subject to the data and discussions with the U.S. Food and Drug Administration.
The speaker said the pancreatic and colorectal studies are expected to be fully enrolled by the end of the year, with the lung study somewhat behind. Readouts are expected in 2027. Bailey said the phase 2 results would be important to any discussions with the FDA about accelerated approval.
Verastem also plans frontline phase 3 trials in the same three cancer types. It expects to begin dosing patients in the pancreatic study by year-end, followed by starts for the lung and colorectal studies the following year.
The planned pancreatic study has three arms: VS-7375 with an anti-EGFR drug, VS-7375 with gemcitabine and nab-paclitaxel chemotherapy, and an investigator’s choice of chemotherapy. Patients in the chemotherapy-only arm would have the option to cross over to Verastem’s drug, the company speaker said.
The speaker said the FDA agreed to overall response rate and progression-free survival as co-primary endpoints, with overall survival as a secondary endpoint. While that design could offer a path to accelerated approval based on response rate, the speaker said the agency had not necessarily agreed to that outcome. Bailey stressed that approval would be a review issue dependent on statistically significant and clinically meaningful data.
Combination data and safety questions
Jefferies analyst Faisal Khurshid asked about early data from Verastem’s China partner, GenFleet, combining VS-7375 with cetuximab. The company speaker said GenFleet reported a 71% response rate in pancreatic cancer in October and described the combination as a potential chemotherapy-free approach. Verastem also plans to evaluate the combination in its phase 2 pancreatic study.
Khurshid noted that GenFleet’s phase 1 safety profile appeared less favorable than that of Verastem’s U.S. study. The company speaker said differences in tolerability had also been observed in other China trials and suggested traditional medicines and a higher background rate of hepatitis as possible contributors. Those explanations were presented as possibilities, not established causes.
Verastem plans to present more data at medical meetings but has not specified which meetings, the speaker said.
Financing and commercial options
Bailey said Verastem’s cash runway extends into the first half of 2028 and assumes phase 2 readouts, the start of phase 3 studies and preparations for commercialization. Asked how the company could fund a large development program independently, he said positive trial results and FDA feedback could attract investor interest and improve access to capital.
“We will get the phase II readouts kind of mid-next year, and we will get a read from the FDA on whether we can get accelerated approval,” Bailey said. “Those are things that are going to, I would imagine, get investor interest.”
About Verastem (NASDAQ:VSTM)
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.
